Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab
CLINICAL CANCER RESEARCH
Coiffier, B; Li, WM; Henitz, ED; Karkera, JD; Favis, R; Gaffney, D; Shapiro, A; Theocharous, P; Elsayed, YA; van de Velde, H; Schaffer, ME; Osmanov, EA; Hong, XN; Scheliga, A; Mayer, J; Offner, F; Rule, S; Teixeira, A; Romejko-Jarosinska, J; de Vos, S; Cr, 2013: Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib-Rituximab Versus Rituximab. CLINICAL CANCER RESEARCH 19(9), p. 2551 - 2561, doi: 10.1158/1078-0432.CCR-12-3069
CEITEC authors: